.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The KRONOS trial compared single-inhaler triple therapy with budesonide, glycopyrrolate and formoterol against the corresponding dual therapies in symptomatic patients with moderate-to-very-severe COPD. Unlike studies restricted to patients with a prior exacerbation, KRONOS did not require a recent exacerbation history, making its population relevant to broader everyday COPD management. Over the study period, triple therapy improved lung function compared with the dual-treatment comparators, with effects that varied according to the comparison and endpoint. The trial also demonstrated that benefit from inhaled corticosteroid-containing triple therapy cannot be judged only by exacerbation history. The practical message is more nuanced: treatment should be individualized around symptom burden, airflow limitation, exacerbation risk and the expected incremental benefit of each component. For NAPCON's COPD-focused sessions, KRONOS provides useful evidence for discussing where triple therapy may fit when dual bronchodilation is not enough. It also supports a structured approach to escalation rather than adding inhaled corticosteroid therapy automatically. As with any COPD regimen, clinicians need to balance efficacy with tolerability and the patient's overall risk profile.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The KRONOS trial compared single-inhaler triple therapy with budesonide, glycopyrrolate and formoterol against the corresponding dual therapies in symptomatic patients with moderate-to-very-severe COPD. Unlike studies restricted to patients with a prior exacerbation, KRONOS did not require a recent exacerbation history, making its population relevant to broader everyday COPD management. Over the study period, triple therapy improved lung function compared with the dual-treatment comparators, with effects that varied according to the comparison and endpoint. The trial also demonstrated that benefit from inhaled corticosteroid-containing triple therapy cannot be judged only by exacerbation history. The practical message is more nuanced: treatment should be individualized around symptom burden, airflow limitation, exacerbation risk and the expected incremental benefit of each component. For NAPCON's COPD-focused sessions, KRONOS provides useful evidence for discussing where triple therapy may fit when dual bronchodilation is not enough. It also supports a structured approach to escalation rather than adding inhaled corticosteroid therapy automatically. As with any COPD regimen, clinicians need to balance efficacy with tolerability and the patient's overall risk profile.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
5 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
